Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis

OBJECTIVE: To assess the efficacy and safety of subcutaneous administration of 30 mg or 80 mg of ozoralizumab plus methotrexate (MTX) in patients with rheumatoid arthritis (RA) whose disease remained active despite MTX therapy. METHODS: In this multicenter, double‐blind, parallel‐group, placebo‐cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Kawanishi, Masafumi, Nakanishi, Megumi, Yamasaki, Hironori, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828347/
https://www.ncbi.nlm.nih.gov/pubmed/35729713
http://dx.doi.org/10.1002/art.42273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828347/
https://www.ncbi.nlm.nih.gov/pubmed/35729713
http://dx.doi.org/10.1002/art.42273

Ejemplares similares